Weekly News Wire | April 14, 2019
Louisiana Awards Subscription Model Contract For Hepatitis C Medications To Asegua Therapeutics
On March 26, 2019, the Louisiana Department of Health (LDH) and Department of Corrections (DOC) announced their selection of Asegua Therapeutics LLC (a subsidiary of Gilead Sciences, Inc.) as their hepatitis C subscription model pharmaceutical partner. A contract is set to be completed by June 1, 2019, with the official start of the subscription model and implementation of the state’s hepatitis C elimination plan anticipated on July 1, 2019. The contract will last five years. Asegua will provide the state with unrestricted access to its direct-acting antiviral medications. Financial details were not disclosed.
Under the contract, Medicaid beneficiaries . . .
Want To Read More? Log In Or Become A Paid Member